Allopurinol, xanthine oxidase, and cardiac ischemia

Journal of Investigative Medicine

Volumn 57, Issue 8, 2009, Pages 902-909

  Lee, Brian E ^a,b   Toledo, Alexander H ^c   Anaya Prado, Roberto ^d   Roach, Richard R ^a   Toledo Pereyra, Luis H ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b WESTERN MICHIGAN UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Western Medical Center   (Mexico)

Author keywords

Allopurinol; ATP; Cardiac ischemia; CHF; Radical oxygen species; Xanthine oxidase

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; AZATHIOPRINE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GOUT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERURICEMIA; MORTALITY; NONHUMAN; OXIDATIVE STRESS; REVIEW; URIC ACID BLOOD LEVEL;

EID: 74249096571     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181bca50c     Document Type: Review

References (76)

1. De Jong JW, Schoemaker RG, De Jonge R. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000;32:2083-2089.
2. Granger DN, Hollwarth ME, Parks DA. Ischemia reperfusion injury: role of oxygen derived free radicals. Acta Physiol Scand. 1986;548: 47-63.
3. McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem. 1968;243:5753-5760.
4. Olsen JS, Ballou DP, Palmer G, et al. The mechanism of action of xanthine oxidase. J Biol Chem. 1974;249:4363-4382.
5. Nakamura S, Yamazaki I. One-electron transfer reactions in biochemical systems IV. A mixed mechanism in the reaction of milk xanthine oxidase with electron acceptors. Biochem Biophys Acta. 1969;189:29-37.
6. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
7. Elion G. The purine path to chemotherapy. Wellcome Research Laboratories, Burroughs Wellcome Co. Nobel lecture; December 8, 1988; Research Triangle Park, NC.
8. Mathru M, Dries DJ, Barnes L, et al. Tourniquet-induced exsanguination in patients requiring lower limb surgery. An ischemia-reperfusion model of oxidant and antioxidant metabolism. Anesthesiology. 1996;84:14-22.
9. Abadeh S, Case PC, Harrison R. Demonstration of xanthine oxidase in human heart. Biochem Soc Trans. 1992;20:346S.
10. Eddy LJ, Stewart JR, Jones HP, et al. Free radical producing enzyme, xanthine oxidase, is undetectable in human hearts. Am J Physiol. 1987;253:H709YH711.
11. Grum CM, Gallaguar KP, Kirsh MM, et al. Absence of detectable xanthine oxidase in human myocardium. J Mol Cell Cardiol. 1989;21:263-267.
12. Li GR, Ferrier GR. Effects of allopurinol on reperfusion arrhythmias in isolated ventricles. Am J Physiol Heart Circ Physiol. 1992;263: 341-348.
13. Moens AL, Claeys MJ, Timmermans JP, et al. Myocardial ischemia/reperfusion-injury; a clinical view on a complex pathophysiological process. Int J Cardiol. 2005;100:179-190.
14. Kimura C, Cheng W, Hisadome K, et al. Superoxide anion impairs contractility in cultured aortic smooth muscle cells. Am J Physiol Heart Circ Physiol. 2002;283;382-390.
15. Kourie JI. Interaction of reactive oxygen species with ion transport mechanisms. Am J Physiol Cell Physiol. 1998;275;1-24.
16. Perez NQ, Gao WD, Marban E. Novel myofilament Ca2+ sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998;83;423-430.
17. Ukai T, Cheng CP, Tachibana H, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing induced heart failure. Circulation. 2001;103;750-755.
18. Boraso A, Ceconi C, Cargnoni A, et al. Oxidative stress and ventricular dysfunction in ischemic heart disease. Heart Fail Rev. 1999;4:147-156.
19. Kielstein JT, Woywodt A, Salpeter SR. Letter by Kielson et al regarding article, High-Dose Allopurinol Improves Endothelial Function byProfoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. Circulation. 2007;115:450-451.
20. DeWall RA, Vasko KA, Stanley EL, et al. Responses of the ischemic myocardium to allopurinol. Am Heart J. 1971;82:362-370.
21. Issel E, Lun A, Pohle R, et al. Hypoxanthine levels in amniotic fluid: an indicator of fetal hypoxia? J Perinat Med. 1982;10:221-225.
22. Kubo SH, Rector TS. Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation. 1991;84: 1589-1596.
23. Ellis SG, Wynne J, Braunwald E, et al. Response of reperfusion-salvaged, stunned myocardium to inotropic stimulation. Am Heart J. 1984;107:13-19.
24. Grupo Italiano per lo Studio della Strepto Chinasi nell'Infarto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;327:397-401.
25. Manning AS, Coltart DJ, Hearse DJ. Ischemia and reperfusionYinduced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res. 1984;55:545-548.
26. Parks DA, Bulkley GB, Granger DN. Role of oxygen-derived free radicals in digestive tract diseases. Surgery. 1983;93:415-422.
27. Reuben GM, Vanhoutte PM. Superoxide anion and hypoxia inactive endothelium-derived relaxing factor. Am J Physiol. 1986;250: H822YH827.
28. Stull LB, Leppo MK, Szweda L, et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95:1005-1011.
29. Taggart DP, Young V, Kemp M, et al. Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Heart. 1994;71:177-181.
30. Kittleson MM, Hare JM. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J. 2005;26:1458-1460.
31. Watts RWE, Watkins PJ, Matthias JQ, et al. Allopurinol and acute uric acid nephropathy. Br Med J. 1966;1:205-208.
32. Yamanaka H, Nishioka K, Suzuki T, et al. Allopurinol metabolism in a patient with xanthine oxidase deficiency. Ann Rheum Dis. 1983;42: 684-686.
33. Lazarus HM, Owens ML, Hopfenbeck A. Allopurinol protection of hepatic nuclear function during hemorrhagic shock. Surg Forum. 1974;25:10-12.
34. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine oxidase and extracellular superoxide dismutase. Circulation. 2002;106:3073-3078.
35. Lee WY, Lee SM. Synergistic protective effect of ischemic preconditioning and allopurinol on ischemia-reperfusion injury in rat liver. Biochem Biophys Res Commun. 2006;349:1087-1093.
36. Anker SD, Doehner D, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
37. Strasak A, Ruttmass E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;54:273-284.
38. Elsayed NM, Nakashima JM, Postlethwait EM. Measurement of uric acid as a marker of oxygen tension in the lung. Arch Biochem Biophys. 1993;302:228-232.
39. Hart L, McGartoll M, Chapman H, et al. The composition of milk xanthine oxidase. J Biol Chem. 1970;116:851-864.
40. Hashimoto Y, Itoh H, Nishida K. Rapid superoxide production by endothelial cells and their injury upon reperfusion. J Surg Res. 1994;57:693-697.
41. Iansek R, Packham D, Aspey BS, et al. An assessment of the possible protective effects of allopurinol in acute stroke. J Neurol Neurosurg Psychiatry. 1986;49:585-587.
42. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159-163.
43. Peronat G. Purine metabolism and hyperuricemia states. The point of view of the rheumatologist. Contrib Nephrol. 2005;147:1-21.
44. Whalen DA, Hamilton DG, Ganote CE, et al. Effect of a transient period of ischemia on myocardial cells. Am J Pathol. 1974;74:381-397.
45. Huizer T, De Jong JW, Nelson JA. Urate production by the human heart. J Cell Mol Cardiol. 1989;21:691-695.
46. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858-865. (Pubitemid 27208159)
47. Massey V, Komai H, Palmer G, et al. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d] pyrimidines. J Biol Chem. 1970;245;2837-2844.
48. Jones CE, Crowell JW, Smith EE. Significance of increased blood uric acid following extensive hemorrhage. Am J Physiol. 1968;214: 1374-1377.
49. Woolliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute illness: a poor prognostic sign. Am J Med. 1982;72:58-62.
50. Hambrecht R, Fiehn E,Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;98:2709-2715.
51. Peterson DA, Asinger RW, Elsperger KL, et al. Reactive oxygen species may cause myocardial reperfusion injury. Biochem Biophys Res Commun. 1985;127:87-93.
52. Olsen JS, Ballou DP, Palmer G, et al. The reaction of xanthine oxidase with molecular oxygen. J Biol Chem. 1974;249;4350-4362.
53. Rundles R, Wyngaarden JT, Hitchings GH, et al. Trans Assoc Am Physicians. 1963;76:126.
54. Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart. 2005;91:707-709.
55. Patel B, Kloner RA. Analysis of reported randomized trials of streptokinase therapy for acute myocardial infarction in the 1980's. Am J Cardiol. 1987;59:501-504.
56. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
57. Hitchings GH Jr. Selective inhibitors of dihydrofolate reductase. Wellcome Research Laboratories, Burroughs Wellcome Co. Nobel lecture; December 8, 1988; Research Triangle Park, NC.
58. McGaurn SP, Davis LE, Krawczeniuk MM. The pharmacokinetics of injectable allopurinol in newborns with hypoplastic left heart syndrome. Pediatrics. 1994;94:820-823.
59. Friedl HP, Till GO, Ryan US. Mediator-induced activation of xanthine oxidase in endothelial cells. J Fed Am Soc Exp Biol. 1989;3: 2512-2518.
60. Berman RS, Martin W. Arterial endothelial barrier dysfunction: actions of the homocysteine and hypoxanthine-xanthine oxidase free radical generating system. Br Med J. 1993;108:920-926.
61. DoehnerW, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2919-12624
62. Ekelund UE, Harrison RW, Shokek O. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999;85:437-445.
63. Cappola TP, Kass DA, Nelson GS. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
64. Adachi H, Motomatsu K, Yara I. Effect of allopurinol (Zyloric) on patients undergoing open heart surgery. Jpn Circ J. 1979;43:395-401.
65. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remolding and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004;110:2175-2179.
66. Kogler H, Fraser H, McCune S, et al. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003;59: 882-1592
67. Farquharson F, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-226.
68. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005;26: 1544-1550.
69. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure. Eur Heart J. 1998;19:1814-1822.
70. Saavedra WF, Paolocci N, St. John ME, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002;90: 297-304.
71. Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalizations in chronic heart failure: a retrospective cohort study. Heart. 2002;87;229-234.
72. Baldus S, Koster R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005;39:1184-1190.
73. Angdin M, Settergren G, Starkopf J, et al. Protective effect of antioxidants on pulmonary endothelial function after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:314-320.
74. Lindsay WG, Toledo-Pereyra LH, Foker JE. Metabolic myocardial protection with allopurinol during cardiopulmonary bypass and aortic cross-clamping. Surg Forum. 1975;26:259.
75. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589-606.
76. Landmesser U, Drexler H. Allopurinol and endothelial function in heart failure: future or fantasy? Circulation. 2002;106:173-175.